1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsFunding Opportunities for Rare Disease Research is sponsored by FDA Office of Orphan Products Development (OOPD). Supports clinical trials of products for rare diseases to address unmet needs.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Skip to in this section menu Medical Products for Rare Diseases and Conditions Grant Programs to Support Development of Medical Products for Rare Diseases Grant Programs to Support Development of Medical Products for Rare Diseases Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Receipt Dates: October 21, 2025; October 20, 2026; October 19, 2027 (for new applications and resubmissions) FOA Number: RFA-FD-25-020 Funding Opportunity Purpose: The purpose of this Notice of Funding Opportunity (NOFO) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions.
Additionally, through the funding of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare diseases and exert a broad and positive impact on rare disease drug development. Learn more about this program: Clinical Trials Grants Program .
Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases Receipt Dates: February 10, 2026; February 8, 2028 (for new applications and resubmissions) FOA Number: RFA-FD-25-017 Funding Opportunity Purpose: The purpose of this notice of funding opportunity (NOFO) is to support efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs.
Through the support of natural history studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and facilitate rare disease product development. Learn more about this program: Natural History Studies Grant Program .
Rare Neurodegenerative Disease Grants Program Opportunities Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required Receipt Dates: October 21, 2025 FOA Number: RFA-FD-25-001 Funding Opportunity Purpose: The purpose of this notice of funding opportunity (NOFO) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare neurodegenerative diseases for children and adults.
Through the support of collaborative, efficient and innovative clinical trials, FDA hopes to exert a broad and positive impact by increasing the number of approved medical products for rare neurodegenerative diseases. See instructions and helpful hints (PDF) for applying for rare neurodegenerative disease grants. Learn more about this program: Rare Neurodegenerative Disease Grants Program .
According to the current listing, eligibility includes: Nonprofits, For-profits, State/local governments, Universities, Hospitals, Research institutions. Confirm the full requirements in the official notice before applying.
Funding Opportunities for Rare Disease Research is funded by FDA Office of Orphan Products Development (OOPD). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The BARK program funds dual-use medical products for warfighters and military working dogs — tourniquets, sensors, drug delivery, and CBRN countermeasures. Proposals close June 3, 2026.
Read articleARPA-H is funding the first agentic AI system that can prescribe medications, monitor patients 24/7, and manage heart disease autonomously. Here is what applicants need to know.
Read article